Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Krebs · SciRah

Researcher profile · Semantic Scholar

M. Krebs

Share profile

M. Krebs — researcher profile on SciRah

h-index: 41
Works: 177
Citations: 11K

Most-cited papers

Lung adenocarcinoma promotion by air pollutants
William Hill, Emilia L. Lim, C. Weeden, Claudia Lee +322 more
2023Nature710 citations Open access
Semantic Scholar
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park, E. Haura, N. Leighl, P. Mitchell +30 more
2021Journal of Clinical Oncology552 citations Open access
Semantic Scholar
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A. Drilon, S. Siena, R. Dziadziuszko, F. Barlesi +32 more
2019The Lancet Oncology445 citations Open access
Semantic Scholar
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
S. Domchek, S. Postel-Vinay, S. Im, Yeon-Hee Park +21 more
2020The Lancet Oncology403 citations Open access
Semantic Scholar
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
C. Abbosh, A. Frankell, T. Harrison, Judit Kisistók +302 more
2023Nature355 citations Open access
Semantic Scholar
The evolution of lung cancer and impact of subclonal selection in TRACERx
A. Frankell, M. Dietzen, Maise Al Bakir, Emilia L. Lim +76 more
2023Nature275 citations Open access
Semantic Scholar
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
A. Sacher, P. Lorusso, M. Patel, Wilson H. Miller +23 more
2023New England Journal of Medicine269 citations Open access
Semantic Scholar
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
D. Rothwell, Mahmood Ayub, N. Cook, F. Thistlethwaite +38 more
2019Nature Medicine250 citations Open access
Semantic Scholar
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
R. Herbst, H. Arkenau, R. Santana-Davila, E. Calvo +18 more
2019The Lancet Oncology230 citations Open access
Semantic Scholar
The evolution of non-small cell lung cancer metastases in TRACERx
Maise Al Bakir, Ariana Huebner, Carlos Martínez-Ruiz, Kristiana Grigoriadis +282 more
2023Nature217 citations Open access
Semantic Scholar
RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy
K. Ng, J. Boumelha, K. Enfield, J. Almagro +327 more
2023Nature202 citations Open access
Semantic Scholar
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
C. Westphalen, M. Krebs, C. le Tourneau, E. Sokol +8 more
2021npj Precision Oncology190 citations Open access
Semantic Scholar
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
K. Simpson, R. Stoney, K. Frese, Nicole Simms +22 more
2020Nature Cancer162 citations
Semantic Scholar
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
A. Drilon, C. Chiu, Yun Fan, B. Cho +16 more
2022JTO Clinical and Research Reports125 citations Open access
Semantic Scholar
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
R. Dziadziuszko, M. Krebs, F. De Braud, S. Siena +15 more
2021Journal of Clinical Oncology122 citations Open access
Semantic Scholar
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
M. Krebs, U. Malapelle, F. André, L. Paz-Ares +5 more
2022JAMA Oncology120 citations Open access
Semantic Scholar
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
T. Yap, M. Krebs, S. Postel-Vinay, Anthony B El-Khouiery +16 more
2021Clinical Cancer Research95 citations Open access
Semantic Scholar
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
C. Lindsay, F. Blackhall, A. Carmel, F. Fernandez-Gutierrez +19 more
2019European Journal of Cancer84 citations Open access
Semantic Scholar
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
K. Litchfield, S. Stanislaw, L. Spain, L. Gallegos +176 more
2020Cell Reports70 citations Open access
Semantic Scholar
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
R. Coombes, S. Howell, S. Lord, L. Kenny +19 more
2023Nature Communications65 citations Open access
Semantic Scholar
Using DNA sequencing data to quantify T cell fraction and therapy response
R. Bentham, K. Litchfield, T. Watkins, Emilia L. Lim +288 more
2021Nature62 citations Open access
Semantic Scholar
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.
M. Krebs, J. Delord, T. R. Jeffry Evans, M. D. de Jonge +12 more
2023Lung Cancer41 citations Open access
Semantic Scholar
Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
M. Krebs, A. Spira, B. Cho, B. Besse +16 more
2022Journal of Clinical Oncology41 citations
Semantic Scholar
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
G. Walls, J. Oughton, A. Chalmers, Sarah R. Brown +22 more
2020Clinical and Translational Radiation Oncology36 citations Open access
Semantic Scholar
MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
B. Cho, R. Doebele, Jessica J. Lin, M. Nagasaka +12 more
202130 citations
Semantic Scholar
Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
S. Siena, R. Doebele, A. Shaw, C. Karapetis +15 more
2019Journal of Clinical Oncology25 citations
Semantic Scholar
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
M. Krebs, J. Blay, C. le Tourneau, D. Hong +3 more
2021ESMO Open24 citations Open access
Semantic Scholar
A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
E. Felip, M. Majem, B. Doger, T. Clay +12 more
2022Journal of Clinical Oncology21 citations
Semantic Scholar
A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.
E. Felip, P. Brunsvig, N. Viñolas, S. Ponce Aix +16 more
2019Journal of Clinical Oncology20 citations
Semantic Scholar
Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
E. Felip, B. Doger, M. Majem, E. Carcereny +7 more
202018 citations Open access
Semantic Scholar
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
G. Saturno, F. Lopes, I. Niculescu-Duvaz, D. Niculescu-Duvaz +19 more
2020Annals of Oncology17 citations Open access
Semantic Scholar
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC.
R. Doebele, L. Perez, H. Trinh, M. Martinec +6 more
2021Journal of Comparative Effectiveness Research16 citations Open access
Semantic Scholar
Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions inKRASmutant cancers
Rajiv Shinde, Angelika Terbuch, M. Little, Reece Caldwell +20 more
2020Tumor Biology16 citations
Semantic Scholar
725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Sri Banerjee, R. Grochot, R. Shinde, J. Lima +14 more
2021Annals of Oncology15 citations Open access
Semantic Scholar
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Athanasios R. Paliouras, M. Buzzetti, Lei Shi, I. Donaldson +10 more
2020EMBO Molecular Medicine15 citations Open access
Semantic Scholar
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.
Jessica J. Lin, A. Drilon, B. Cho, E. Felip +16 more
2023Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
Bernard Gaston Doger de Spéville, E. Felip, M. Forster, M. Majem +7 more
2023Journal of Clinical Oncology13 citations Open access
Semantic Scholar
Phase I cancer trials: a qualitative study of specialist palliative care
S. Bellhouse, Lucy Galvin, L. Turner, Sally Taylor +4 more
2019BMJ Supportive & Palliative Care13 citations Open access
Semantic Scholar
Oncology patients’ experiences in experimental medicine cancer trials: a qualitative study
C. Sawyer, L. Preston, Sally Taylor, M. Davies +6 more
2021BMJ Open12 citations Open access
Semantic Scholar
Digital ECMT Cancer Trial Matching Tool: an Open Source Research Application to Support Oncologists in the Identification of Precision Medicine Clinical Trials
Paul O'Regan, Richard Hoskins, Christopher Grave, J. Stevenson +5 more
2023JCO Clinical Cancer Informatics11 citations Open access
Semantic Scholar
11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
M. Majem, M. Forster, M. Krebs, J. Peguero +8 more
2023Journal of Thoracic Oncology11 citations Open access
Semantic Scholar
265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
S. Howell, M. Krebs, S. Lord, L. Kenny +16 more
2021Annals of Oncology11 citations Open access
Semantic Scholar
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer
Victoria Foy, C. Lindsay, A. Carmel, F. Fernandez-Gutierrez +18 more
2021Translational Lung Cancer Research11 citations Open access
Semantic Scholar
Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.
A. Minchom, M. Krebs, B. Cho, Se-Hoon Lee +13 more
2023Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases.
Qing Zhang, Jessica J. Lin, N. Pal, L. Polito +6 more
2023JTO Clinical and Research Reports9 citations Open access
Semantic Scholar
Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
J. Desai, Sae-Won Han, Jong-Seok Lee, E. Shacham-Shmueli +27 more
2023Cancer Research8 citations
Semantic Scholar
Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
C. Westphalen, M. Krebs, C. le Tourneau, E. Sokol +8 more
2021npj Precision Oncology8 citations Open access
Semantic Scholar
Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.
M. Krebs, A. Branson, S. Barber, C. Poile +13 more
2023Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
M. Krebs, Rajiv Shinde, R. Rahman, R. Grochot +12 more
2021Clinical Trials7 citations
Semantic Scholar
230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
M. Krebs, S. Lord, L. Kenny, R. Baird +11 more
2021Annals of Oncology7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Blackhall×10
Invite
F. Blackhall — researcher profile on SciRah
C. Dive×10
Invite
C. Dive — researcher profile on SciRah
Martin D. Forster×9
Invite
Martin D. Forster — researcher profile on SciRah
L. Priest×8
Invite
L. Priest — researcher profile on SciRah

×8

Invite

C. Hiley — researcher profile on SciRah

Invite

B. Cho — researcher profile on SciRah

Invite

S. Veeriah — researcher profile on SciRah

C. Naceur-Lombardelli×7

Invite

C. Naceur-Lombardelli — researcher profile on SciRah

Maise Al Bakir×7

Invite

Maise Al Bakir — researcher profile on SciRah

N. Mcgranahan×7

Invite

N. Mcgranahan — researcher profile on SciRah

Invite

A. Hackshaw — researcher profile on SciRah

Invite

M. Carter — researcher profile on SciRah